The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis
Abstract
OBJECTIVES: To examine the relationship between patient-reported depression and adherence to therapy with interferon beta-1b (IFN beta-1b) and to test the hypothesis that treatment of depression is associated with improved adherence. DESIGN: Patients with multiple sclerosis were followed up 6 months after initiating therapy with IFN beta-1b. SETTING: A university outpatient multiple sclerosis center, an academic group practice, and a health maintenance organization. PATIENTS: Eighty-five patients with clinically evident multiple sclerosis taking IFN beta-1b. MAIN OUTCOME MEASURE: Follow-up questionnaire. RESULTS: Thirty-five (41%) of the 85 patients reported new or increased depression within 6 months of initiating therapy with IFN beta-1b. Patients experiencing symptoms of depression were more likely to discontinue therapy. Among the patients reporting new or increased depression, 86% who received psychotherapy or antidepressant medication and 38% of the patients who received no therapy for depression continued the IFN beta-1b therapy (P = .003). Although psychotherapy was used as a treatment option more frequently in university and academic group practice-based multiple sclerosis clinics than in the health maintenance organization (P = .02), the treatment adherence patterns were similar across sites. CONCLUSIONS: These findings support previous findings that patients report increased depression after initiating therapy with IFN beta-1b. Although the source of this depression is unclear, these findings suggest that treating patient-reported depression increases adherence to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Stone, L. A., Frank, J. A., Albert, P. S., Bash, C., Smith, M. E., Maloni, H., & McFarland, H. F. (1995) · Annals of Neurology · doi:10.1002/ana.410370511 · Cited by 247
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1777 · Cited by 202
Side effect profile of interferon beta-lb in MS
Neilley, L. K., Goodin, D. S., Goodkin, D. E., & Hauser, S. L. (1996) · Neurology · doi:10.1212/wnl.46.2.552 · Cited by 150
Self-citationMultiple sclerosis and gestation
Poser, S., & Poser, W. (1983) · Neurology · doi:10.1212/wnl.33.11.1422 · Cited by 139
Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200502 · Cited by 131
Self-citationInterferon beta treatment for multiple sclerosis: persisting questions
Goodkin, D. E. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100605 · Cited by 15
Self-citation
Cited by
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis
Boeschoten, R. E., Braamse, A. M. J., Beekman, A. T. F., Cuijpers, P., van Oppen, P., Dekker, J., & Uitdehaag, B. M. J. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.11.067 · Cited by 713
Ziegelstein, R. C., Fauerbach, J. A., Stevens, S. S., Romanelli, J., Richter, D. P., & Bush, D. E. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.12.1818 · Cited by 710
Major depression in multiple sclerosis: A population-based perspective
Patten, S. B., Beck, C. A., Williams, J. V. A., Barbui, C., & Metz, L. M. (2003) · Neurology · doi:10.1212/01.wnl.0000095964.34294.b4 · Cited by 529
Metadata
- Authors
- Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 1997-05-01
- Volume
- 54
- Issue
- 5
- Pages
- 531-533
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1970190011
- Cited by
- 307
- References
- 10
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis. https://app.cochat.ai/papers/10.1001/archneur.1997.00550170015009
- The paper
- Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997). Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis. Archives of Neurology. https://doi.org/10.1001/archneur.1997.00550170015009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.